1,028
Views
0
CrossRef citations to date
0
Altmetric
Research Papers

Synthesis and structure–activity relationships for some novel diflapolin derivatives with benzimidazole subunit

, , , , , ORCID Icon, , ORCID Icon, , & ORCID Icon show all
Pages 1752-1764 | Received 08 Jan 2022, Accepted 05 Jun 2022, Published online: 20 Sep 2022

References

  • Meirer K, Steinhilber D, Proschak E. Inhibitors of the arachidonic acid cascade: interfering with multiple pathways. Basic Clin Pharmacol Toxicol 2014;114:83–91.
  • Haeggström JZ. Leukotriene biosynthetic enzymes as therapeutic targets. J Clin Invest 2018;128:2680–90.
  • Hanna VS, Hafez EAA. Synopsis of arachidonic acid metabolism: a review. J Adv Res 2018;11:23–32.
  • Dinarello CA. Anti-inflammatory agents: present and future. Cell 2010;140:935–50.
  • Temml V. Dissertation: molecular modeling and computational investigation of targets within the inflammatory cascade. Innsbruck 2014:27–30.
  • He C, Wu Y, Lai Y, et al. Dynamic eicosanoid responses upon different inhibitor and combination treatments on the arachidonic acid metabolic network. Mol Biosyst 2012;8:1585–94.
  • Abramovitz M, Wong E, Cox ME, et al. 5-lipoxygenase-activating protein stimulates the utilization of arachidonic acid by 5-lipoxygenase. Eur J Biochem 1993;215:105–11.
  • Rådmark O, Werz O, Steinhilber D, Samuelsson B. 5-Lipoxygenase, a key enzyme for leukotriene biosynthesis in health and disease. Biochim Biophys Acta 2015;1851:331–9.
  • Gerstmeier J, Weinigel C, Rummler S, et al. Time-resolved in situ assembly of the leukotriene-synthetic 5-lipoxygenase/5-lipoxygenase-activating protein complex in blood leukocytes. FASEB J 2016;30:276–85.
  • Gerstmeier J, Weinigel C, Barz D, et al. An experimental cell-based model for studying the cell biology and molecular pharmacology of 5-lipoxygenase-activating protein in leukotriene biosynthesis. Biochim Biophys Acta 2014;1840:2961–9.
  • Steinhilber D, Hofmann B. Recent advances in the search for novel 5-lipoxygenase inhibitors. Basic Clin Pharmacol Toxicol 2014;114:70–7.
  • Chiasson AI, Robichaud S, Ndongou Moutombi FJ, et al. New zileuton-hydroxycinnamic acid hybrids: synthesis and structure-activity relationship towards 5-lipoxygenase inhibition. Molecules 2020;25:4686.
  • Fischer L, Hornig M, Pergola C, et al. The molecular mechanism of the inhibition by licofelone of the biosynthesis of 5-lipoxygenase products. Br J Pharmacol 2007;152:471–80.
  • Spector AA. Arachidonic acid cytochrome P450 epoxygenase pathway. J Lipid Res 2009;50 Suppl:S52–S56.
  • Liu JY, Yang J, Inceoglu B, et al. Inhibition of soluble epoxide hydrolase enhances the anti-inflammatory effects of aspirin and 5-lipoxygenase activation protein inhibitor in a murine model. Biochem Pharmacol 2010;79:880–7.
  • Thomson SJ, Askari A, Bishop-Bailey D. Anti-inflammatory effects of epoxyeicosatrienoic acids. Int J Vasc Med 2012;2012:605101.
  • Szczeklik A. The cyclooxygenase theory of aspirin-induced asthma. Eur Respir J 1990;3:588–93.
  • Hiesinger K, Wagner KM, Hammock BD, et al. Development of multitarget agents possessing soluble epoxide hydrolase inhibitory activity. Prostaglandins Other Lipid Mediat 2019;140:31–9.
  • Zhang CY, Duan JX, Yang HH, et al. COX-2/sEH dual inhibitor PTUPB alleviates bleomycin-induced pulmonary fibrosis in mice via inhibiting senescence. FEBS J 2020;287:1666–80.
  • Meirer K, Glatzel D, Kretschmer S, et al. Design, synthesis and cellular characterization of a dual inhibitor of 5-lipoxygenase and soluble epoxide hydrolase. Molecules 2016;22:45.
  • Temml V, Garscha U, Romp E, et al. Discovery of the first dual inhibitor of the 5-lipoxygenase-activating protein and soluble epoxide hydrolase using pharmacophore-based virtual screening. Sci Rep 2017;7:42751.
  • Waltenberger B, Garscha U, Temml V, et al. Discovery of potent soluble epoxide hydrolase (sEH) inhibitors by pharmacophore-based virtual screening. J Chem Inf Model 2016;56:747–62.
  • Garscha U, Romp E, Pace S, et al. Pharmacological profile and efficiency in vivo of diflapolin, the first dual inhibitor of 5-lipoxygenase-activating protein and soluble epoxide hydrolase. Sci Rep 2017;7:017–09795.
  • Vieider L, Romp E, Temml V, et al. Synthesis, biological evaluation and structure-activity relationships of diflapolin analogues as dual sEH/FLAP inhibitors. ACS Med Chem Lett 2019;10:62–6.
  • Leeman AH, Hammond ML, Maletic M, et al. Preparation of 4-benzimidazolylmethoxy-3-halophenylmethoxybenzoates and analogs as tRNA synthetase inhibitors (WO2000066120A1). New Jersey: Merck & Co., Inc., Cubist Pharmaceuticals Inc.; 2000.
  • Morisseau C, Goodrow MH, Newman JW, et al. Structural refinement of inhibitors of urea-based soluble epoxide hydrolases. Biochem Pharmacol 2002;63:1599–608.
  • Ménard L, Pilote S, Naccache PH, et al. Inhibitory effects of MK-886 on arachidonic acid metabolism in human phagocytes. Br J Pharmacol 1990;100:15–20.
  • Ho JD, Lee MR, Rauch CT, et al. Structure-based, multi-targeted drug discovery approach to eicosanoid inhibition: dual inhibitors of mPGES-1 and 5-lipoxygenase activating protein (FLAP). Biochim Biophys Acta Gen Subj 2021;1865:129800.
  • Sacks D, Baxter B, Campbell BCV, et al. Multisociety consensus quality improvement revised consensus statement for endovascular therapy of acute ischemic stroke. Int J Stroke 2018;13:612–32.
  • Heinisch G, Huber E, Matuszczak B, et al. Pyridazines 82. Synthesis of pyridazino [3,4-b][1,5]benzodiazepin-5-ones and their biological evaluation as non-nucleoside HIV reverse transcriptase inhibitors. Arch Pharm 1997;330:29–34.
  • Kocienski PJ. Protecting groups (Thieme foundations of organic chemistry series). New York: Georg Thieme Verlag Stuttgart; 1994.
  • Boyum A. Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest 1968;97:77–89.
  • Steinhilber D, Herrmann T, Roth HJ. Separation of lipoxins and leukotrienes from human granulocytes by high-performance liquid chromatography with a Radial-Pak cartridge after extraction with an octadecyl reversed-phase column. J Chromatogr Biomed Appl 1989;493:361–6.
  • Hawkins PCD, Skillman AG, Warren GL, et al. Conformer generation with OMEGA: algorithm and validation using high quality structures from the protein databank and cambridge structural database. J Chem Inf Model 2010;50:572–84.
  • Jones G, Willett P, Glen RC, et al. Development and validation of a genetic algorithm for flexible docking. J Mol Biol 1997;267:727–48.
  • Kubinyi HF. Wilson analysis. Theory, applications and its relationship to Hansch analysis. Quant Struct Act Relat 1988;7:121–33.
  • Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep 2017;7:42717.
  • Daina A, Michielin O, Zoete V. iLOGP: a simple, robust, and efficient description of n-octanol/water partition coefficient for drug design using the GB/SA approach. J Chem Inf Model 2014;54:3284–301.
  • Daina A, Zoete V. A BOILED-egg to predict gastrointestinal absorption and brain penetration of small molecules. ChemMedChem 2016;11:1117–21.